ClinicalTrials.gg
Active, not recruitingNCT04517786Updated May 3, 2023

MINIject (MINI SO627) in Patients With Open Angle Glaucoma Using Single Operator Delivery Tool

An interventional study of MINIject CS627 implant in Glaucoma, Open-Angle Glaucoma Eye, sponsored by iSTAR Medical. Active, not recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-03.

Sponsored by iSTAR Medical · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Glaucoma with a site in India — none open to participants now, 1 under way, none of them phase 3. Glaucoma · India.

Enrollment
18th of 18
21 · median 79
Started
2021
with 1 other
No phase
7 of 22
none open now
Registered
21st of 22
by date
Lead sponsor
2 of 22
iSTAR Medical

Among the 22 studies in Glaucoma with a site in India, this one is the 18th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2021, is one of 7 with no phase, and was the 21st registered.

Glaucoma

1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.

Browse Glaucoma studies →

Open to participants now

None of the 22 studies in Glaucoma with a site in India is open now. The open studies under Glaucoma, anywhere →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies in Glaucoma with a site in India as a file.
02

Study summary

The study will assess safety and performance in patients with open-angle glaucoma uncontrolled by topical hypotensive medications who had previously been implanted with a MINIject glaucoma implant.

Read the detailed description

The study will evaluate the efficacy and safety of MINI SO627 and IOP (Intra- ocular pressure) lowering effects with or without the use of glaucoma medications. The procedure will be a stand alone surgery. Patient follow up with several examinations up to 24 months after surgery.

The primary endpoint is the reduction in medicated mean diurnal IOP at 6 months follow up compared to medicated diurnal IOP at baseline visit.

03

Conditions studied

  • Glaucoma, Open-Angle Glaucoma Eye

Browse trials for

Keywords

  • Glaucoma
  • Medical device
  • MIGS drainage device
  • eye reduction IOP
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of primary or secondary open angle glaucoma during screening/baseline visit or earlier.
  • Grade 3 or grade 4 according to Shaffer Angle Grading System.
  • Glaucoma not adequately controlled by one to four different topical hypotensive medication(s), given each for at least one month, as confirmed by 21mmHg \< IOP \< 35 mmHg in the study eye at baseline visit.

Exclusion criteria

Exclusion Criteria:

  • Grade 2 (narrow, 20 degrees), grade 1 (extremely narrow, less or equal to 10 degrees) and grade 0 (closed or slit) according to Shaffer Angle Grading System in the study eye.
  • Neovascular glaucoma in the study eye.
  • Corneal opacity or iridocorneal angle not visible through gonioprism in the study eye, preventing correct placement of the implant in the stud eye.
  • Prior glaucoma surgery in the study eye.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    MINIject CS627 implant

    MINIject 627 implant is used to reduce intra-ocular pressure in the eye. It is implanted through a minimally-invasive glaucoma surgical intervention in a stand alone procedure.

    Device: MINIject CS627 implant

Interventions

  • DeviceMINIject CS627 implant

    MINI SO627 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant (CS627) and a single operator delivery tool. The delivery tool is a single-use tool, designed for inserting the CS627 implant into the suprachoroidal space in the eye.

06

What researchers measure

Primary outcomes

  1. Change in medicated or unmedicated (without washout) mean diurnal IOP at 6 months follow-up

    The primary endpoint of the study is the reduction in medicated or unmedicated (without washout) mean diurnal IOP at 6 months follow-up compared to medicated or unmedicated (without washout) diurnal IOP at baseline visit.

    Time frame: 6 month post surgey

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in May 2022, 16 months.

Of 58 industry-sponsored interventional studies with no phase under Glaucoma, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 46. This study's 16 months is below that.

Counting every sponsor, half of 288 studies reached it within 30 months; a quarter within 12 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2020
First posted
Aug 18, 2020
StartActual
Jan 15, 2021
Primary completionActual
May 16, 2022
CompletionEst.
Dec 31, 2023
Last update
May 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04517786
Lead sponsor
iSTAR Medical
Collaborators
International Drug Development Institute
Responsible party
Sponsor
First posted
Aug 18, 2020
Start date
Jan 15, 2021
Primary completion
May 16, 2022
Completion
Dec 31, 2023 (estimated)
Last update
May 3, 2023

Study contacts

Zubair Hussain, PhD
study director · iSTAR

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion